Literature DB >> 3980073

Permeability-increasing ability of PAF-acether in rat skin.

B Gerdin, C Lundberg, G Smedegøard.   

Abstract

Platelet-activating factor (PAF-acether), a phospholipid compound with effects on several cells, e.g., platelets and polymorphonuclear leukocytes (PMNs), was examined for its effect on microvascular permeability in rat skin. It was found to increase microvascular permeability, measured as exudation of [125I]human serum albumin, in amounts exceeding 1 pmol, and was more than 1000 times as potent as histamine. The effect was independent of cell infiltration, as no accumulation of PMNs, measured as the amount of myeloperoxidase in the skin, occurred and as the response was unaltered in animals rendered neutropenic due to treatment with an antiserum against PMNs.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3980073     DOI: 10.1007/bf00915417

Source DB:  PubMed          Journal:  Inflammation        ISSN: 0360-3997            Impact factor:   4.092


  11 in total

1.  Paf-acether (platelet-activating factor) increases microvascular permeability and affects endothelium-granulocyte interaction in microvascular beds.

Authors:  J Björk; L Lindbom; B Gerdin; G Smedegård; K E Arfors; J Benveniste
Journal:  Acta Physiol Scand       Date:  1983-11

2.  Use of 125I-labeled human serum albumin for quantitation of microvascular permeability in rat skin: reevaluation of an old method for studies on substances with an enhancing effect on microvascular permeability.

Authors:  B Gerdin
Journal:  J Pharmacol Methods       Date:  1981-11

3.  Anaphylactic actions of platelet-activating factor.

Authors:  N P Stimler; C M Bloor; T E Hugli; R L Wykle; C E McCall; J T O'Flaherty
Journal:  Am J Pathol       Date:  1981-10       Impact factor: 4.307

4.  Vasoactive properties of acetyl glyceryl ether phosphorylcholine and analogues.

Authors:  D M Humphrey; L M McManus; K Satouchi; D J Hanahan; R N Pinckard
Journal:  Lab Invest       Date:  1982-04       Impact factor: 5.662

5.  Vascular actions of synthetic PAF-acether (a synthetic platelet-activating factor) in the rat: evidence for a platelet independent mechanism.

Authors:  M Sánchez-Crespo; F Alonso; P Iñarrea; V Alvarez; J Egido
Journal:  Immunopharmacology       Date:  1982-04

6.  Acute microvascular effects of PAF-acether, as studied by intravital microscopy.

Authors:  J Björk; G Smedegård
Journal:  Eur J Pharmacol       Date:  1983-12-09       Impact factor: 4.432

7.  PAF-acether-induced plasma exudation in rat skin is independent of platelets and neutrophils.

Authors:  E Pirotzky; C P Page; R Roubin; A Pfister; W Paul; J Bonnet; J Benveniste
Journal:  Microcirc Endothelium Lymphatics       Date:  1984-02

8.  Increase in vascular permeability induced by leukotriene B4 and the role of polymorphonuclear leukocytes.

Authors:  J Björk; P Hedqvist; K E Arfors
Journal:  Inflammation       Date:  1982-06       Impact factor: 4.092

9.  Effects of heterologous antineutrophil serum in guinea pigs. Hematologic and ultrastructural observations.

Authors:  D M Simpson; R Ross
Journal:  Am J Pathol       Date:  1971-10       Impact factor: 4.307

10.  Polymorphonuclear leukocyte accumulation in inflammatory dermal sites as measured by 51Cr-labeled cells and myeloperoxidase.

Authors:  C Lundberg; K E Arfors
Journal:  Inflammation       Date:  1983-09       Impact factor: 4.092

View more
  3 in total

1.  Mechanism of prostaglandin E2 inhibition of acute changes in vascular permeability.

Authors:  K R McLeish; S R Wellhausen; G T Stelzer
Journal:  Inflammation       Date:  1987-09       Impact factor: 4.092

2.  Mechanism by which methylprednisolone inhibits acute immune complex-induced changes in vascular permeability.

Authors:  K R McLeish; F N Miller; G T Stelzer; S R Wellhausen
Journal:  Inflammation       Date:  1986-09       Impact factor: 4.092

3.  Pharmacologic analysis of 1-0-alkyl-2-acetyl-sn-glycero-3-phosphocholine-induced increases in cutaneous vascular permeability in the rat.

Authors:  E J Kusner; C D Knee; R D Krell
Journal:  Agents Actions       Date:  1987-02
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.